[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1074264T3 - Inhibitorer for neovaskularisering - Google Patents

Inhibitorer for neovaskularisering

Info

Publication number
DK1074264T3
DK1074264T3 DK99912129T DK99912129T DK1074264T3 DK 1074264 T3 DK1074264 T3 DK 1074264T3 DK 99912129 T DK99912129 T DK 99912129T DK 99912129 T DK99912129 T DK 99912129T DK 1074264 T3 DK1074264 T3 DK 1074264T3
Authority
DK
Denmark
Prior art keywords
neovascularization
acid sequence
amino acid
hgf
polypeptide
Prior art date
Application number
DK99912129T
Other languages
English (en)
Inventor
Toshikazu Nakamura
Original Assignee
Toshikazu Nakamura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toshikazu Nakamura filed Critical Toshikazu Nakamura
Application granted granted Critical
Publication of DK1074264T3 publication Critical patent/DK1074264T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99912129T 1998-04-28 1999-04-06 Inhibitorer for neovaskularisering DK1074264T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13468198 1998-04-28
PCT/JP1999/001834 WO1999055361A1 (fr) 1998-04-28 1999-04-06 Inhibiteurs de neovascularisation

Publications (1)

Publication Number Publication Date
DK1074264T3 true DK1074264T3 (da) 2008-11-24

Family

ID=15134093

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99912129T DK1074264T3 (da) 1998-04-28 1999-04-06 Inhibitorer for neovaskularisering

Country Status (9)

Country Link
US (1) US20090023658A1 (da)
EP (1) EP1074264B1 (da)
JP (1) JP4094814B2 (da)
AT (1) ATE408415T1 (da)
CA (1) CA2327382C (da)
DE (1) DE69939586D1 (da)
DK (1) DK1074264T3 (da)
ES (1) ES2313777T3 (da)
WO (1) WO1999055361A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001284576A1 (en) 2000-08-28 2002-03-13 Fariba Nayeri The synergetic effects of hgf and antibacterial treatment
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
FR2831540B1 (fr) * 2001-10-31 2004-07-09 Inst Vaisseaux Et Du Sang Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques
JP2003250549A (ja) * 2002-02-25 2003-09-09 Kringle Pharma Inc Ｎｋ４遺伝子または組換えｎｋ４蛋白質からなる医薬
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
JP4716741B2 (ja) * 2004-01-27 2011-07-06 敏一 中村 糖鎖欠損型ＨＧＦα鎖部分蛋白質
WO2009125831A1 (ja) * 2008-04-11 2009-10-15 有限会社スリーピー Ｎｋ４に対するモノクローナル抗体
MX2017016774A (es) * 2015-06-25 2018-05-14 Taiho Pharmaceutical Co Ltd Agente terapeutico para la fibrosis.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133492T2 (de) * 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
ATE355379T1 (de) * 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
MX9708217A (es) * 1995-04-26 1997-12-31 Childrens Medical Center Fragmentos de angiostatina y angiostatina agregada y metodos de uso.
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6855685B2 (en) * 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP2003250549A (ja) * 2002-02-25 2003-09-09 Kringle Pharma Inc Ｎｋ４遺伝子または組換えｎｋ４蛋白質からなる医薬

Also Published As

Publication number Publication date
WO1999055361A1 (fr) 1999-11-04
EP1074264A4 (en) 2004-11-10
CA2327382C (en) 2012-12-18
CA2327382A1 (en) 1999-11-04
EP1074264B1 (en) 2008-09-17
EP1074264A1 (en) 2001-02-07
ES2313777T3 (es) 2009-03-01
US20090023658A1 (en) 2009-01-22
ATE408415T1 (de) 2008-10-15
DE69939586D1 (de) 2008-10-30
JP4094814B2 (ja) 2008-06-04

Similar Documents

Publication Publication Date Title
NO20025450D0 (no) Ny farmasöytisk sammensetning
DE69220861D1 (de) Zyklische Peptide und ihre Verwendung
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
FI962591A0 (fi) Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
DE69131759D1 (de) An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one
DE69228749D1 (de) Neuartige polypeptide und ihre verwendung
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DK1074264T3 (da) Inhibitorer for neovaskularisering
NO984950L (no) Forbindelser med veksthormonfrigj°rende egenskaper
DE60228136D1 (de) Cytokin-proteinfamilie
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
RS49520B (sr) Antimikrobno aktivne smeše
DK162839C (da) N,3-diacyl-2-oxindol-1-carboxamid-forbindelser og 3-acyl-2-oxindol-forbindelser til anvendelse som mellemprodukter ved deres fremstilling
AR008695A1 (es) Composiciones farmaceuticas estabilizadas, basadas en la asociacion de quinupristina / dalfopristina; procedimiento para prepararlas, utilizacion dedichas composiciones y utilizacion del acido metansulfonico o del acido clorhidrico en la estabilizacion de dichas composiciones.
DE69619530D1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen